Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

Overview of attention for article published in BMC Infectious Diseases, April 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 19,744 followers.

Boceprevir for Previously Untreated Pts w Chronic HCV Genotype 1 - US Cost-Effectiveness Study http://t.co/UxjSa5wR96 RT @BMC_series

Boceprevir for naïve patients with chronic hepatitis C G1 infection: a US-based cost-effectiveness modeling study. http://t.co/Hy3ki9O5Ok

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection. #mdart #md http://t.co/gD2NVrEblK

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection. #mdart #md http://t.co/f5XQacGayB

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.